Lantheus Holdings (LNTH) Non-Current Debt (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Non-Current Debt of $569.6 million for Q1 2026, up 0.62% year-over-year from $566.1 million in Q1 2025, and little changed quarter-over-quarter from $568.7 million in Q4 2025.
Lantheus Holdings (LNTH) Non-Current Debt (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Non-Current Debt for 13 consecutive years, with $569.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt rose 0.62% year-over-year to $569.6 million; the TTM figure through Mar 2026 stood at $569.6 million (up 0.62% YoY), while the FY2025 annual figure was $568.7 million, up 0.6% from the prior year.
- Non-Current Debt held at $569.6 million in Q1 2026 per LNTH's latest filing, from $568.7 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $569.6 million in Q1 2026 and bottomed at $613000.0 in Q3 2024.
- Historically, Non-Current Debt has averaged $458.6 million across 5 years, with a median of $561.7 million in 2023.
- Annual changes were most pronounced in 2024 — Non-Current Debt tumbled 99.89% — and 2025, when it surged 92548.78%.
- Lantheus Holdings' Non-Current Debt stood at $557.7 million in 2022, then gained by 0.71% to $561.7 million in 2023, then climbed by 0.64% to $565.3 million in 2024, then advanced by 0.6% to $568.7 million in 2025, then advanced by 0.16% to $569.6 million in 2026.
- Business Quant data shows LNTH's Non-Current Debt at $569.6 million in Q1 2026, $568.7 million in Q4 2025, and $567.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 130.00 Mn |
| 10 | Lantheus Holdings | 6.54 Bn | 5.94 Bn | 241.86 Mn | 570.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 570.35 Mn |
| Mar 31, 2026 | 569.60 Mn |
| Dec 31, 2025 | 568.68 Mn |
| Sep 30, 2025 | 567.94 Mn |
| Jun 30, 2025 | 566.85 Mn |
| Mar 31, 2025 | 566.10 Mn |
| Dec 31, 2024 | 565.28 Mn |
| Sep 30, 2024 | 613,000.00 |
| Jun 30, 2024 | 563.19 Mn |
| Mar 31, 2024 | 562.47 Mn |
| Dec 31, 2023 | 561.67 Mn |
| Sep 30, 2023 | 560.58 Mn |
| Jun 30, 2023 | 559.24 Mn |
| Mar 31, 2023 | 558.54 Mn |
| Dec 31, 2022 | 557.71 Mn |
| Sep 30, 2022 | 152.06 Mn |
| Jun 30, 2022 | 155.66 Mn |
| Mar 31, 2022 | 159.37 Mn |
| Dec 31, 2021 | 163.12 Mn |
| Sep 30, 2021 | 166.74 Mn |